logo-loader
viewIntrommune Therapeutics

Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

Intrommune Therapeutics CEO Michael Nelson sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New York-based biotechnology company is developing is developing an oral mucosal immunotherapy treatment platform to treat food allergies including peanut allergies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator’s 'solid pandemic plan' to see company much stronger on other side

Xpediator (LON:XPD) chief financial officer Robert Ross joins Steve Darling from Proactive ahead of its AGM. Ross talks about its pandemic management plan, its pipeline of acquisition opportunities and how financially secure the company is.

1 hour, 23 minutes ago

2 min read